HUM vs UNH: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

UNH is the larger of the two ($357.88B market cap): the incumbent the market prices for continued execution (17.12x forward earnings, beta 0.52). HUM is the smaller challenger ($51.70B), actually pricier on forward earnings (24.79x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

HUM vs UNH: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricHUMUNHWhat it tells you
Market cap$51.70B$357.88BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E24.7917.12Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E42.0022.80Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta0.640.52Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range91% of range70% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book2.753.65How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: UNH is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how HUM and UNH affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HUM and UNH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HUM and UNH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Humana (HUM) do?

Humana Inc. is a Louisville-based health and well-being company best known as one of the two largest Medicare Advantage insurers in the country, alongside UnitedHealth. Its Insurance segment covered roughly 7.1 million individual and group Medicare Advantage members as of early 2026, plus Medicaid, military (TRICARE), and pharmacy-benefit members. The core economics turn on the medical loss ratio, the share of premium dollars paid out as medical claims, and on CMS star ratings, which determine quality-bonus payments that fund richer plan benefits.

Full HUM guide

What does UnitedHealth Group (UNH) do?

UnitedHealth Group is the largest US health insurer and one of the largest healthcare companies in the world. It runs through two main engines. UnitedHealthcare is the insurance arm, providing employer, individual, Medicare Advantage, and Medicaid health plans to tens of millions of members. Optum is the faster-growing health-services arm: Optum Health (physician groups and care delivery, including value-based care), Optum Insight (healthcare data, analytics, and technology), and Optum Rx (one of the largest pharmacy benefit managers in the country). The combination lets UnitedHealth manage both the financing and the delivery of care, capturing margin across the system and using vast claims data to manage costs. Headquartered in Minnetonka, Minnesota, UnitedHealth is a Dow component and one of the largest companies in the S&P 500 by revenue. Its scale, vertical integration, and Medicare Advantage leadership define its competitive position.

Full UNH guide

HUM vs UNH: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • HUM drivers: Demographic tailwind in Medicare Advantage; CenterWell healthcare services.
  • UNH drivers: Optum growth engine; Medicare Advantage scale.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove the earnings pressure of 2024-2025. For UNH, unitedHealth faces a difficult medical-cost environment: rising utilization (especially in Medicare Advantage) can spike the medical loss ratio and compress margins, as the company has experienced.

HUM or UNH: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick HUM if you believe its drivers more; UNH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HUM and UNH guides.

HUM vs UNH: the full fundamentals

HUM. At about $417, Humana trades near 39x trailing earnings, a figure inflated by depressed recent profits, and about 24x analysts' 2027 estimate, which assumes earnings nearly double next year as the margin recovery and star-ratings bonuses arrive. The stock trades at only about 0.34x sales, typical of a thin-margin insurer. Q3 2026 results are scheduled for November 6, with consensus calling for a seasonal loss of about $1.00 per share on revenue near $40.9 billion.

UNH. The trailing P/E of about 26x is inflated by the near-zero fourth quarter of 2025; on forward earnings UNH trades near 17x, closer to its historical range. Revenue is enormous but insurance margins are thin, so the valuation hinges on whether the medical cost trend keeps stabilizing and the raised 2026 outlook holds. The stock has recovered a large part of its 2025 decline, which leaves less of a discount for regulatory and cost risk than a year ago.

Headline figures (approximate, October 2026): HUM shows revenue (ttm) ~$146 billion, revenue growth (q2 2026, yoy) ~26%, operating / net margin (ttm) ~3.5% / ~0.9%, adjusted eps (2026 / 2027 consensus) ~$9.16 / ~$17.09; UNH shows revenue (ttm) ~$450 billion; Q3 2026 ~$112.7 billion, ~flat year on year, operating margin ~5.8% (net margin ~3.5%), net income (ttm) ~$15.9 billion (sensitive to medical costs), eps ~$15.55 trailing; Q3 2026 $4.69 vs $4.14 consensus.

The bottom line: HUM vs UNH

HUM and UNH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HUM and UNH exposure against your real portfolio. It is not an investment adviser.

Wondering how HUM or UNH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Humana

Ask Walnut's AI anything about HUM and see how it fits what you own.

FAQ

What is the difference between HUM and UNH?

+

Humana Inc. UnitedHealth Group is the largest US health insurer and one of the largest healthcare companies in the world. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is HUM or UNH the better stock?

+

Neither is universally better. UNH is the larger incumbent; HUM is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, HUM or UNH?

+

On forward P/E (as of November 2026), HUM trades at 24.79x and UNH at 17.12x, so UNH is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both HUM and UNH?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of HUM vs UNH?

+

HUM: The medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove the earnings pressure of 2024-2025. Margins remain thin, with a trailing operating margin near 3.5% and net margin under 1%. Earnings are also seasonal: consensus calls for an adjusted loss of about $1.00 per share in Q3 2026 and about $7.86 in Q4, as Medicare Advantage costs build through the year. Star ratings are a second lever; the 2027 rebound helps, but ratings are recalculated every year and a slip would reduce CMS quality-bonus payments. Medicare Advantage reimbursement and broader healthcare policy are set by the government and can change rate updates, risk-adjustment rules, or audit intensity. Finally, aggressive membership growth or repricing, such as the 2027 PPO exits, can pressure profitability or cause member attrition if benefits are trimmed too far, and after a roughly 58% rally in 2026 more of the recovery is already priced in. UNH: UnitedHealth faces a difficult medical-cost environment: rising utilization (especially in Medicare Advantage) can spike the medical loss ratio and compress margins, as the company has experienced. Regulatory and political risk is significant, including Medicare Advantage rate changes, scrutiny of PBM practices, and proposals to limit insurer-provider integration. The company has faced antitrust attention, a major cyberattack on its Change Healthcare unit, and intense public criticism of the insurance industry. Reimbursement is set by government programs that can change with each cycle. Litigation, regulatory fines, and reputational risk are persistent. Its size makes it a target for legislation, and any sustained period of elevated medical costs directly pressures earnings. The 2026 recovery also raises the bar: at roughly 17x forward earnings the stock now prices in continued margin repair, and the September quarter's net income of about $4.1 billion was lower than the $6.3 billion and $5.5 billion of the first two quarters, so the seasonal pattern of medical costs remains a swing factor.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell HUM or UNH; figures are approximate and dated (as of November 2026). Verify current data before investing.